Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q86X45
UPID:
DAA11_HUMAN
Alternative names:
Leucine-rich repeat-containing protein 6; Leucine-rich testis-specific protein; Protein tilB homolog; Testis-specific leucine-rich repeat protein
Alternative UPACC:
Q86X45; Q13648; Q4G183
Background:
Dynein axonemal assembly factor 11, also known as Leucine-rich repeat-containing protein 6, plays a pivotal role in dynein arm assembly, crucial for cilia and spermatozoal flagella motility. It ensures the transport of outer dynein arm proteins to cilia, facilitating respiratory function and male fertility.
Therapeutic significance:
Its association with Primary Ciliary Dyskinesia, particularly Ciliary dyskinesia, primary, 19, underscores its therapeutic potential. Understanding the role of Dynein axonemal assembly factor 11 could open doors to potential therapeutic strategies for treating respiratory and fertility-related disorders.